Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical and Molecular Characteristics of Foveal Sparing Phenotype in Chinese Patients With Inherited Retinal Diseases. | Transl Vis Sci Technol | 2026 | 41700794 | PubTator, text mining | PubMed |
| Gene therapy outcomes in young patients with RPE65-retinal degeneration. | Can J Ophthalmol | 2026 | 41679721 | PubTator, text mining | PubMed |
| Combination gene therapy with AAV based RPE65 and survivin vectors sustains phenotypic rescue in neural retina of LCA2 mice. | Mol Cell Biochem | 2026 | 41632426 | PubTator, text mining | PubMed |
| CR2-fH, A Targeted Inhibitor of Alternative Complement Pathway Reduces Dry AMD-Like Phenotype in AMD Patient iPSC-derived RPE Cells. | Invest Ophthalmol Vis Sci | 2026 | 41631752 | PubTator, text mining | PubMed |
| Pathogenicity and Functional Analysis of Multi-Variant Allele of RPE65 Causing Retinitis Pigmentosa. | Transl Vis Sci Technol | 2026 | 41626883 | PubTator, text mining | PubMed |
| Illuminating retinoid flux in the neurosensory retina. | J Clin Invest | 2026 | 41623170 | PubTator, text mining | PubMed |
| The molecular renaissance: Navigating the biological boundaries of vision. | Indian J Ophthalmol | 2026 | 41581026 | PubTator, text mining | PubMed |
| Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review. | Biomol Biomed | 2026 | 41569064 | PubTator, text mining | PubMed |
| PRPF8 Mutation-Induced Defects in Human iPSC-Derived RPE Are Rescued by Adenine Base Editing. | Invest Ophthalmol Vis Sci | 2026 | 41533919 | PubTator, text mining | PubMed |
| Exploring extracellular vesicle MicroRNAs in Usher syndrome type 1B: Tear-Derived EVs as potential indicators of retinal health. | Cell Mol Life Sci | 2026 | 41528484 | PubTator, text mining | PubMed |
| Adhesive bioactive materials in ocular applications: Toward smart, regenerative, and minimally invasive therapies. | Bioact Mater | 2026 | 41492365 | PubTator, text mining | PubMed |
| Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy. | JAMA Ophthalmol | 2026 | 41481309 | PubTator, text mining | PubMed |
| Harnessing retinoic acid metabolism-related genes to identify lung adenocarcinoma subtype and establish a risk model for predicting prognosis and drug therapy response. | Comput Biol Chem | 2026 | 41391260 | PubTator, text mining | PubMed |
| Chorioretinal Atrophy after Voretigene Neparvovec Therapy in <italic>RPE65</italic> Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging. | Ophthalmologica | 2026 | 41379738 | PubTator, text mining | PubMed |
| Discovery of rare and novel variants in inherited retinal disorders: Exome sequencing analysis of six Iranian families. | J Investig Med | 2026 | 41217041 | PubTator, text mining | PubMed |
| Measuring historical variant reclassification in inherited retinal disease and its impact on clinical genetic testing. | Ophthalmic Genet | 2026 | 41057982 | PubTator, text mining | PubMed |
| Deciphering the genetic basis of inherited retinal dystrophies via whole-exome sequencing in a Turkish cohort. | Mol Vis | 2025 | 41867366 | PubTator, text mining | PubMed |
| Dynamic Inner Blood Retina Barrier Disruption in Retinitis Pigmentosa. | Invest Ophthalmol Vis Sci | 2025 | 41533932 | PubTator, text mining | PubMed |
| Exome sequencing identifies novel genetic variants in patients with atypical Non-Syndromic retinitis pigmentosa. | Mol Biol Rep | 2025 | 41460542 | PubTator, text mining | PubMed |
| Mechanism of Lutein to meso-Zeaxanthin Isomerization by RPE65 Catalysis. | bioRxiv | 2025 | 41415389 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=3